List view / Grid view
31 July 2015 | By Victoria White
Eisai and Halozyme are to collaborate to evaluate Halaven in combination with PEGPH20 in first line HER2-negative metastatic breast cancer...
31 July 2015 | By Victoria White
The EC has approved the use of Perjeta in combination with Herceptin and chemotherapy for use before surgery in patients with early stage breast cancer...
24 July 2015 | By Victoria White
A study of more than 30,000 women shows that aromatase inhibitors substantially reduce the risk of death in postmenopausal women ER-positive breast cancer...
21 July 2015 | By Victoria White
BioMarin has provided an update on the ABRAZO Phase 2 study of its poly ADP-ribose polymerase (PARP) inhibitor, talazoparib...
9 July 2015 | By Victoria White
Around half of all breast cancer patients could one day benefit from having the cheap and widely-available hormone progesterone added to their treatment...
29 June 2015 | By Victoria White
The CHMP has recommended that the EC approves the use of Perjeta for the neoadjuvant treatment of adult patients with HER2-positive early breast cancer...
1 June 2015 | By Victoria White
Roche has announced new results from the Phase II NeoSphere study that assessed a Perjeta regimen in people with HER2-positive early breast cancer...
1 April 2015 | By Victoria White
Peregrine has announced promising clinical data from a Phase I trial evaluating bavituximab therapy in patients with metastatic breast cancer...
30 September 2014 | By Roche
Roche announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives of people with previously untreated HER2-positive metastatic breast cancer...
25 September 2014 | By Roche
Roche announced results from the phase III IMELDA study which showed that the combination of Avastin (bevacizumab) plus Xeloda (capecitabine) chemotherapy as a maintenance treatment following initial induction treatment with Avastin-based therapy resulted in clinically meaningful gains in overall survival...
23 September 2014 | By The Institute of Cancer Research
Even long stretches of DNA that contain no genes at all can affect the risk of breast cancer, by physically interacting with genes elsewhere, a new study reports...
20 November 2013 | By Roche
Kadcyla is indicated as a single agent for the treatment of adults with HER2-positive, unresectable locally advanced or metastatic breast cancer...
30 September 2013 | By Roche
Use of new Herceptin formulation reduced the time needed for pharmacists and doctors to treat patients...
28 September 2013 | By Roche
Kadcyla nearly doubled the time that patients lived without their disease worsening compared with treatment of physician’s choice...
2 September 2013 | By Roche
Roche announced that a new injectable (subcutaneous) formulation of Herceptin (trastuzumab) has been approved by the European Commission...
